- 相关的突触核蛋白病：α-突触核蛋白靶向化合物的主要候选对象。
-Associated Synucleinopathies: Prime Candidates for Alpha-Synuclein Targeting Compounds.
作者信息
Brockmann Kathrin
机构信息
Center of Neurology, Department of Neurodegeneration and Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
German Center for Neurodegenerative Disease (DZNE), Bonn, Germany.
出版信息
Front Cell Dev Biol. 2020 Sep 25;8:562522. doi: 10.3389/fcell.2020.562522. eCollection 2020.
With disease-modifying compounds targeting alpha-synuclein available in clinical trials, patient stratification according to alpha-synuclein-specific enrichment strategies is a much-needed prerequisite. Such a scenario will be exemplified for , one major genetic risk factor that is specifically associated with the alpha-synucleinopathies: Parkinson's disease and dementia with Lewy bodies.
随着针对α-突触核蛋白的疾病修饰化合物进入临床试验，根据α-突触核蛋白特异性富集策略对患者进行分层是一项迫切需要的前提条件。这种情况将以 为例进行说明， 是一种主要的遗传风险因素，与α-突触核蛋白病（帕金森病和路易体痴呆）有特异性关联。 （注：原文中“for ”和“ ”处内容缺失，翻译时保留原文格式）
Zotero 插件